ArticleProceedings of the National Academy of Sciences of the United States of America1997
Transloading of tumor antigen-derived peptides into antigen-presenting cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 53 citations in OpenAlex.
- Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice.NPJ vaccines · 2025Article
- Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.International journal of molecular sciences · 2024Review
- TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.JCI insight · 2021Article
- How arginine derivatives alter the stability of lipid membranes: dissecting the roles of side chains, backbone and termini.European biophysics journal : EBJ · 2021Article
- Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.EBioMedicine · 2021Article
- Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.Scientific reports · 2019Article
- Vaccine Potentiation by Combination Adjuvants.Vaccines · 2014Review
- Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.Journal of virology · 2005Article
- Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.Journal of molecular medicine (Berlin, Germany) · 2004Article
- Biological applications of protein transduction technology.Trends in biotechnology · 2003Review
- In vivo plasmid DNA electroporation generates exceptionally high levels of epitope-specific CD8+ T-cell responses.Gene therapy · 2003Article
- Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.Molecular biotechnology · 2001Review
- The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- The immunologist's grail: vaccines that generate cellular immunity.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.Pathology oncology research : POR · 1997Article
- Cell-free tumor antigen peptide-based cancer vaccines.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of a steadily growing number of tumor antigens (TAs) has made generic, cell-free, peptide-based cancer vaccines a possible alternative to cytokine-transfected autologous cellular cancer vaccines. The major drawback of peptide vaccines, however, is the poor immunogenicity of peptides. It is commonly thought that for the induction of an effective anticancer immune response, antigen-presenting cells (APCs) have to display TA-derived peptides to T lymphocytes. Polycationic amino acids have been employed in the past to enhance transport of proteins into cells. In a systematic study, the ability of different cationic polymers to transfer fluorescence-tagged peptides to APCs was investigated. We were able to show that several compounds enhance uptake of fluorescence-labeled peptides by APCs to different degrees. The most efficient compound identified, polyarginine (pArg), enhanced peptide delivery by more than 2 logs as compared with cells treated with peptide alone, whereas polylysine (pLys) treatment resulted in approximately 10-fold increased levels of fluorescence. Augmentation of peptide uptake was concentration-dependent, and the molecular weight of pArg or pLys also influenced peptide delivery. Furthermore, highly negatively charged peptides appear to be delivered with higher efficiency, although neutral peptides were also taken up at enhanced rates. Whereas peptide uptake mediated by pLys appears to be due to an at least transient permeabilization of cell membranes, peptide delivery in the presence of pArg may rely on endocytic processes. TA-derived peptides applied as cancer vaccines in conjunction with polycations afforded antitumor protection in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.